nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

01.12.2010 | Original Research

DNMT3B −579 G>T Promoter Polymorphism and Risk of Gallbladder Carcinoma in North Indian Population

verfasst von: Kshitij Srivastava, Anvesha Srivastava, Balraj Mittal

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Aim

Carcinoma of gallbladder (GBC) is a relatively rare but highly fatal disease. The DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B) −579 G>T promoter polymorphism (rs1569686) influences gene function and has been associated with various malignancies. Present population-based case-control study was undertaken to examine the potential association of DNMT3B −579 G>T variation with GBC in North Indian population.

Methods

Genotypes and allelic frequencies of the DNMT3B −579 G>T polymorphism were determined for 212 GBC patients and 219 controls using PCR-RFLP. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated for the association of DNMT3B polymorphism with GBC. Analysis of potential transcription factor binding sites was also identified in the region harboring the polymorphism.

Results

The DNMT3B −579 G>T polymorphism was found to be non-significantly associated with an overall increased risk of GBC (OR = 1.10 and 1.56 for T/G and G/G genotypes, respectively, P _trend = 0.227). The increased risk was predominant in both male and female cohorts and also non-significantly in GBC patients with gallstone status (OR = 1.44; P = 0.280, OR = 1.06; P = 0.804 and OR = 1.45; P = 0.143, respectively).

Conclusion

DNMT3B −579 G>T polymorphism may alter susceptibility to GBC although it may not play a major role in the pathoetiology of this disease in North Indian population.

Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64.CrossRefPubMed

Hoi-Hung C, Tin-Lap L, Owen MR, Wai-Yee C. DNA methylation of cancer genome Birth Defects Research Part C: Embryo Today. Reviews. 2009;87:335–50.

Yen RW, Vertino PM, Nelkin BD, Yu JJ, el-Deiry W, Cumaraswamy A, et al. Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res. 1992;20:2287–91.CrossRefPubMed

Xie S, Wang Z, Okano M, Nogami M, Li Y, He WW, et al. Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene. 1999;236:87–95.CrossRefPubMed

Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000;9:2395–402.CrossRefPubMed

Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer. 2008;7:15.CrossRefPubMed

Tian Z, Zhang ZY, Li L, Li J (2006) [Expression of DNA methyltransferases in salivary adenoid cystic carcinoma and its association with the CpG islands methylation of tumor suppressor genes] Zhonghua Kou Qiang Yi Xue Za Zhi 41:411–415

Vallbohmer D, Brabender J, Yang D, Schneider PM, Metzger R, Danenberg KD, et al. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer. 2006;8:39–44.CrossRefPubMed

Xiong Y, Dowdy SC, Xue A, Shujuan J, Eberhardt NL, Podratz KC, et al. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers. Gynecol Oncol. 2005;96:601–9.CrossRefPubMed

10.

Yakushiji T, Uzawa K, Shibahara T, Noma H, Tanzawa H. Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity. Int J Oncol. 2003;22:1201–7.PubMed

11.

Guo X, Zhang L, Wu M, Wang N, Liu Y, Er L, et al. Association of the DNMT3B polymorphism with colorectal adenomatous polyps and adenocarcinoma. Mol Biol Rep. 2010;37:219–25.CrossRefPubMed

12.

Hong YS, Lee HJ, You CH, Roh MS, Kwak JY, Lee MJ, et al. DNMT3b 39179GT polymorphism and the risk of adenocarcinoma of the colon in Koreans. Biochem Genet. 2007;45:155–63.CrossRefPubMed

13.

Lee SJ, Jeon HS, Jang JS, Park SH, Lee GY, Lee BH, et al. DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis. 2005;26:403–9.CrossRefPubMed

14.

Wang L, Rodriguez M, Kim ES, Xu Y, Bekele N, El-Naggar AK, et al. A novel C/T polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3B6 is associated with prognosis in head and neck cancer. Int J Oncol. 2004;25:993–9.PubMed

15.

Fan H, Liu DS, Zhang SH, Hu JB, Zhang F, Zhao ZJ. DNMT3B 579 G > T promoter polymorphism and risk of esophagus carcinoma in Chinese World. J Gastroenterol. 2008;14:2230–4.

16.

International Union Against Cancer (UICC) (2002) TNM classification of malignant tumours, 6th ed, Sobin LH, Wittekind Ch (ed.), New York, Wiley-Liss:pp. 184–187

17.

Devlin B, Roeder K. Genomic control for association studies. Biometrics. 1999;55:997–1004.CrossRefPubMed

18.

Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1995;11:375–86.CrossRef

19.

Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis. 2002;23:381–7.CrossRefPubMed

20.

Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ. 1995;311:1145–8.PubMed

21.

Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–42.CrossRefPubMed

22.

Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol. 2002;2:S1–15.PubMed

23.

Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res. 1994;22:4673–80.CrossRefPubMed

24.

National Cancer Registry Programme (2002) Two-year report of the Population Based Cancer Registries 1997–1998. New Delhi: Indian Council of Medical Research

25.

Hsing AW, Sakoda LC, Rashid A, Andreotti G, Chen J, Wang BS, et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Res. 2008;68:6442–52.CrossRefPubMed

26.

Srivastava A, Srivastava K, Pandey S, Choudhuri G, Mittal B. Single-nucleotide polymorphisms of DNA repair genes OGG1 and XRCC1: association with gallbladder cancer in North Indian population. Ann Surg Oncol. 2009;16:1695–703.CrossRefPubMed

27.

Srivastava K, Srivastava A, Pandey S, Kumar A, Mittal B. Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population. J Gastroenterol. 2009;44:774–80.CrossRefPubMed

28.

Park SK, Andreotti G, Sakoda LC, Gao YT, Rashid A, Chen J, et al. Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China. Carcinogenesis. 2009;30:606–14.CrossRefPubMed

29.

Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163–7.CrossRefPubMed

30.

Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168–74.CrossRefPubMed

31.

Yanagisawa Y, Ito E, Yuasa Y, Maruyama K. The human DNA methyltransferases DNMT3A and DNMT3B have two types of promoters with different CpG contents. Biochim Biophys Acta. 2002;1577:457–65.PubMed

32.

Diehl AK. Gallstone size and the risk of gallbladder cancer. JAMA. 1983;250:2323–6.CrossRefPubMed

Titel: DNMT3B −579 G>T Promoter Polymorphism and Risk of Gallbladder Carcinoma in North Indian Population
verfasst von: Kshitij Srivastava
Anvesha Srivastava
Balraj Mittal
Publikationsdatum: 01.12.2010
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 4/2010
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-010-9156-x

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

DNMT3B −579 G>T Promoter Polymorphism and Risk of Gallbladder Carcinoma in North Indian Population

Abstract